Form 4: Amneal CFO Konidaris Boosts Stake with RSU Vesting
Insider Transaction Report
Amneal Pharmaceuticals' EVP & CFO Tasos Konidaris increased his direct ownership of Class A Common Stock through the vesting of restricted stock units, including performance-based units that achieved a 200% vesting threshold.
Summary
- Tasos Konidaris, Executive Vice President & CFO of Amneal Pharmaceuticals, Inc., acquired a total of 629,865 shares of Class A Common Stock through the vesting of restricted stock units (RSUs) and performance-based restricted stock units (PBRSUs) on March 3 and March 4, 2026.
- A significant portion of these shares, 458,716, came from performance-based restricted stock units granted on March 3, 2023, which vested at 200% of the targeted number due to the Issuer's Class A Common Stock achieving certain average closing prices over a three-year performance period.
- To satisfy tax withholding obligations related to these vestings, Konidaris disposed of a total of 286,583 shares of Class A Common Stock at prices of $13.31 and $13.30.
- Following these transactions, Konidaris's direct beneficial ownership of Class A Common Stock increased to 449,434 shares.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive filing, primarily due to the 200% vesting of performance-based restricted stock units, which signals strong achievement of internal stock performance targets.
Positives
- Performance-based restricted stock units granted on March 3, 2023, vested at 200% of the targeted number, indicating strong company performance relative to the set thresholds.
- The EVP & CFO's direct beneficial ownership of Class A Common Stock increased to 449,434 shares after the transactions, aligning management's interests with shareholders.
Negatives
- A substantial number of shares (286,583) were disposed of to cover tax withholding obligations, which is a common practice but reduces the immediate net share accumulation.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that the vesting of performance-based restricted stock units at 200% suggests Amneal Pharmaceuticals' stock performance met or exceeded aggressive internal targets, which can be a positive signal for investor confidence in the company's strategic execution within the pharmaceutical sector.
Comparison to Industry Standards
- StockSavvy.ai observes that the vesting of performance-based restricted stock units at 200% is a strong indicator of outperformance against internal benchmarks, which is generally considered superior to typical industry compensation structures that might only vest at 100% or less if targets are not met. While specific comparable companies or projects are not detailed in this filing, achieving such a high vesting percentage implies robust stock price appreciation or operational success relative to peers in the pharmaceutical industry during the performance period.
Stakeholder Impact
- Shareholders: Increased alignment of executive interests with shareholder value due to increased direct ownership and successful performance-based vesting.
- Employees: May signal a positive outlook for the company's performance, potentially boosting morale and confidence in leadership.
Key Dates
| Date | Description |
|---|---|
| 03/03/2022 | Grant date for 181,159 restricted stock units to the reporting person, vesting in four equal installments beginning on the first anniversary. |
| 03/03/2023 | Grant date for 229,358 restricted stock units to the reporting person, vesting in four equal installments beginning on the first anniversary. |
| 03/03/2023 | Grant date for performance-based restricted stock units to the reporting person, scheduled to vest based on Class A Common Stock achieving certain average closing prices over a three-year performance period. |
| 03/04/2024 | Grant date for 175,926 restricted stock units to the reporting person, vesting in four equal installments beginning on the first anniversary. |
| 03/03/2025 | Grant date for 114,155 restricted stock units to the reporting person, vesting in four equal installments beginning on the first anniversary. |
| 03/03/2026 | Vesting and settlement date for various restricted stock units and performance-based restricted stock units, and associated tax withholding transactions. |
| 03/04/2026 | Vesting and settlement date for restricted stock units and associated tax withholding transactions. |
| 03/05/2026 | Signature date of the reporting person's attorney-in-fact for the Form 4 filing. |
Recommendation
holdThe vesting of performance-based restricted stock units at 200% is a strong positive signal, indicating the company met or exceeded its stock performance targets. This aligns management's interests with shareholders and suggests underlying strength. However, this is an insider transaction report, not a comprehensive financial statement, so a 'hold' recommendation is appropriate to acknowledge the positive signal without overstating its impact on a broader investment thesis, pending further financial disclosures.
Keywords
Amneal Pharmaceuticals, AMRX, Tasos Konidaris, SEC Form 4, Insider Transaction, Restricted Stock Units, Performance-Based RSUs, Stock Vesting, Executive Compensation, Share Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.